Skip to Content
  • Previous Rank
    248
  • Revenues ($M)
    $12,273.90
  • Revenue Percent Change
    7.2%
  • Profits ($M)
    $2,539.10
  • Profits Percent Change
    -31.4%
  • Assets ($M)
    $23,652.60
  • Employees
    7,300
  • Market Value — as of March 29, 2018 ($M)
    $57,930.10

The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases, and hemophilia. It also makes and sells biosimilars of advanced biologics.

Company Info

CEO
Michel Vounatsos
CEO Title
Chairman & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Cambridge, Mass.
Websitehttp://www.biogen.com
Years on Fortune 500 List9
Employees7,300
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Biogen Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$12,273.907.2%
Profits ($M)$2,539.10-31.4%
Assets ($M)$23,652.60-
Total Stockholder Equity ($M)$12,612.80-
Market Value — as of March 29, 2018 ($M)$57,930.10-

Profit Ratios

Profit as % of Revenues20.7%
Profits as % of Assets10.7%
Profits as % of Stockholder Equity20.1%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)11.92
EPS % Change (from 2016)-29.6%
EPS % Change (5 year annual rate)15.7%
EPS % Change (10 year annual rate)19.6%

Total Return

Total Return to Investors (2017)21.8%
Total Return to Investors (5 year, annualized)18.7%
Total Return to Investors (10 year, annualized)19.8%